Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
Source: Cell & Gene
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.
        access the Video!
        
            Log In
        
    
    
    
    Get unlimited access to:
            Trend and Thought Leadership Articles
            
        
        
            Case Studies & White Papers
            
        
        
            Extensive Product Database
            
        
        
            Members-Only Premium Content
            
        
    
        Welcome Back! Please Log In to Continue.
        
            X
        
    
    Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
        Subscribe to Cell & Gene
        X
    
    
        Subscribe to Cell & Gene